GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.
TableEdit
PMID:16227987
You don't have sufficient rights on this wiki to edit tables. Perhaps you need to log in. Changes you make in the Table editor will not be saved back to the wiki
See Help for Help on this wiki. See the documentation for how to use the table editor
Citation |
LaVoie, MJ, Ostaszewski, BL, Weihofen, A, Schlossmacher, MG and Selkoe, DJ (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11:1214-21 |
---|---|
Abstract |
Inherited mutations in PARK2, the gene encoding parkin, cause selective degeneration of catecholaminergic neurons in the substantia nigra and locus coeruleus of the brainstem, resulting in early-onset parkinsonism. But the role of parkin in common, sporadic forms of Parkinson disease remains unclear. Here we report that the neurotransmitter dopamine covalently modifies parkin in living dopaminergic cells, a process that increases parkin insolubility and inactivates its E3 ubiquitin ligase function. In the brains of individuals with sporadic Parkinson disease, we observed decreases in parkin solubility consistent with its functional inactivation. Using a new biochemical method, we detected catechol-modified parkin in the substantia nigra but not other regions of normal human brain. These findings show a vulnerability of parkin to modification by dopamine, the principal transmitter lost in Parkinson disease, suggesting a mechanism for the progressive loss of parkin function in dopaminergic neurons during aging and sporadic Parkinson disease. |
Links |
PubMed Online version:10.1038/nm1314 |
Keywords |
Adult; Animals; Blotting, Western; Brain Chemistry; CHO Cells; Carbon Radioisotopes/metabolism; Cell Line; Cells, Cultured; Cricetinae; Dopamine/metabolism; Dopamine/toxicity; Dopamine Agents/pharmacology; Dose-Response Relationship, Drug; Female; Humans; Locus Coeruleus/cytology; Locus Coeruleus/metabolism; Methamphetamine/pharmacology; Mutation; Neurons/drug effects; Parkinson Disease/genetics; Parkinson Disease/metabolism; Precipitin Tests; Solubility; Substantia Nigra/cytology; Substantia Nigra/metabolism; Ubiquitin-Protein Ligases/chemistry; Ubiquitin-Protein Ligases/genetics; Ubiquitin-Protein Ligases/metabolism |
public |
Cancel |